Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federico Cappuzzo

Showing results (21-30 of 275) with videos related to

Pageof 28
Sort By:
Future Oncology (London, England)|February 12, 2010
Clinical implications of MET gene copy number in lung cancerLuca Toschi, Federico Cappuzzo
The Oncologist|February 14, 2007
Understanding the new genetics of responsiveness to epidermal growth factor receptor tyrosine kinase inhibitorsLuca Toschi, Federico Cappuzzo
Oncotargets and Therapy|July 10, 2010
Gemcitabine for the treatment of advanced nonsmall cell lung cancerLuca Toschi, Federico Cappuzzo
Expert Opinion on Pharmacotherapy|October 11, 2014
Management of NSCLC: focus on crizotinibLorenza Landi, Federico Cappuzzo
Journal of Thoracic Disease|November 22, 2016
Immunotherapy and lung cancer: from therapeutic cancer vaccination to novel approachesValentina Mazza, Federico Cappuzzo
Expert Review of Respiratory Medicine|April 3, 2020
Determining the appropriate treatment for different EGFR mutations in non-small cell lung cancer patientsSimona Scodes, Federico Cappuzzo
Expert Review of Anticancer Therapy|October 19, 2013
HER2 and lung cancerLorenza Landi, Federico Cappuzzo
ISRN Molecular Biology|July 12, 2016
K-Ras Mutations in Non-Small-Cell Lung Cancer: Prognostic and Predictive ValueManolo D'Arcangelo, Federico Cappuzzo
The Application of Clinical Genetics|August 11, 2017
Treating <i>EGFR</i> mutation resistance in non-small cell lung cancer - role of osimertinibValentina Mazza, Federico Cappuzzo
Journal of Thoracic Disease|September 22, 2017
A few pills twice a day keep ALK-positive non-small-cell lung cancer at bayLorenza Landi, Federico Cappuzzo
Pageof 28

Showing results (21-30 of 275) with videos related to

Sort By:
Pageof 28
Future Oncology (London, England)|February 12, 2010
Clinical implications of MET gene copy number in lung cancerLuca Toschi, Federico Cappuzzo
The Oncologist|February 14, 2007
Understanding the new genetics of responsiveness to epidermal growth factor receptor tyrosine kinase inhibitorsLuca Toschi, Federico Cappuzzo
Oncotargets and Therapy|July 10, 2010
Gemcitabine for the treatment of advanced nonsmall cell lung cancerLuca Toschi, Federico Cappuzzo
Expert Opinion on Pharmacotherapy|October 11, 2014
Management of NSCLC: focus on crizotinibLorenza Landi, Federico Cappuzzo
Journal of Thoracic Disease|November 22, 2016
Immunotherapy and lung cancer: from therapeutic cancer vaccination to novel approachesValentina Mazza, Federico Cappuzzo
Expert Review of Respiratory Medicine|April 3, 2020
Determining the appropriate treatment for different EGFR mutations in non-small cell lung cancer patientsSimona Scodes, Federico Cappuzzo
Expert Review of Anticancer Therapy|October 19, 2013
HER2 and lung cancerLorenza Landi, Federico Cappuzzo
ISRN Molecular Biology|July 12, 2016
K-Ras Mutations in Non-Small-Cell Lung Cancer: Prognostic and Predictive ValueManolo D'Arcangelo, Federico Cappuzzo
The Application of Clinical Genetics|August 11, 2017
Treating <i>EGFR</i> mutation resistance in non-small cell lung cancer - role of osimertinibValentina Mazza, Federico Cappuzzo
Journal of Thoracic Disease|September 22, 2017
A few pills twice a day keep ALK-positive non-small-cell lung cancer at bayLorenza Landi, Federico Cappuzzo
Pageof 28